Updates are available Correction dated 2024-03-18
Click to view Correction: https://doi.org/10.1007/s00198-024-07048-x
-
Authors
Brandi, Maria Luisa https://orcid.org/0000-0002-8741-0592
Khan, Aliya A. https://orcid.org/0000-0003-3733-8956
Rush, Eric T. https://orcid.org/0000-0002-8147-7315
Ali, Dalal S. https://orcid.org/0000-0002-5378-5548
Al-Alwani, Hatim https://orcid.org/0000-0001-9036-7903
Almonaei, Khulod https://orcid.org/0000-0002-7293-2654
Alsarraf, Farah https://orcid.org/0000-0001-9426-9702
Bacrot, Severine https://orcid.org/0000-0001-9311-5664
Dahir, Kathryn M. https://orcid.org/0000-0002-9980-9138
Dandurand, Karel https://orcid.org/0000-0003-1759-8419
Deal, Chad https://orcid.org/0000-0002-7591-4718
Ferrari, Serge Livio https://orcid.org/0000-0002-1372-4417
Giusti, Francesca https://orcid.org/0000-0002-8576-9606
Guyatt, Gordon https://orcid.org/0000-0003-2352-5718
Hatcher, Erin https://orcid.org/0000-0002-3638-4742
Ing, Steven W. https://orcid.org/0000-0002-4343-6723
Javaid, Muhammad Kassim https://orcid.org/0000-0001-7985-0048
Khan, Sarah https://orcid.org/0000-0003-3604-303X
Kocijan, Roland https://orcid.org/0000-0002-2618-1546
Lewiecki, E. Michael https://orcid.org/0000-0003-2026-9587
Linglart, Agnes https://orcid.org/0000-0003-3455-002X
M’Hiri, Iman https://orcid.org/0000-0002-6151-3366
Marini, Francesca https://orcid.org/0000-0002-3678-4922
Nunes, Mark E. https://orcid.org/0000-0001-6338-1726
Rockman-Greenberg, Cheryl https://orcid.org/0000-0002-4741-8442
Seefried, Lothar https://orcid.org/0000-0003-1154-3388
Simmons, Jill H. https://orcid.org/0000-0002-4189-6718
Starling, Susan R. https://orcid.org/0000-0003-1813-5600
Ward, Leanne M. https://orcid.org/0000-0003-1557-9185
Yao, Liang https://orcid.org/0000-0003-4068-3136
Brignardello-Petersen, Romina https://orcid.org/0000-0002-6010-9900
Roux, Christian https://orcid.org/0000-0002-9598-9346
- License Information
-
More Information
Article History
Received: 6 July 2023
Accepted: 10 July 2023
First Online: 20 November 2023
Change Date: 18 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00198-024-07048-x
Declarations
:
: These papers are retrospective reviews and did not require ethics committee approval.
: MLB has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB, grants and/or speaker for Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, UCB, consultant for Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB. AAK has received research grants from Alexion, Amgen, Ascendis, Chugai, Radius, Takeda, Ultragenyx and is on the advisory board for Amgen, Amolyt, and Takeda. ETR has consulted for, received honoraria from, and has research supported by Alexion Pharmaceuticals and AstraZeneca Rare Disease. SB has received advisory board participation from Alexion. KMD has received research grants and honoraria from Alexion. CD serves as an investigator, consultant, and speaker for Amgen; investigator for Radius; speaker for Alexion. SWI has received grant funding, ad hoc advisory board participation from Alexion Pharmaceuticals. MKJ has received honoraria and grants from UCB, Amgen, Kyowa Kirin, Sanofi, Besin Healthcare, AbbVie. RK is a speaker and has received research funding from Alexion, AstraZeneca Rare Disease. EML serves as an investigator, consultant, and speaker for Amgen; investigator for Radius; speaker for Alexion. AL is a consultant for and has received research funding and honoraria from Alexion. MEN serves as a non-paid consultant (fee equivalent donated to 501(c)3 patient advocacy groups) for Alexion. CR-G is a member of the Scientific Advisory Board of the HPP Global Patient Registry sponsored by Alexion AstraZeneca Rare Disease. She has had received honoraria for participation on this Board and has also received honoraria for select Alexion-sponsored presentations. CR has received research grants and honoraria from Alexion, Kyowa Kirin, Regeneron. LS has received honoraria and grants from Alexion, Amgen, Chiesi, KyowaKirin, Novartis, Theramex, UCB. JHS serves as an Investigator and consultant for Alexion. SRS has received honoraria from and has research supported by Alexion Pharmaceuticals, AstraZeneca Rare Disease. LMW serves as a consultant to Alexion. DSA, HA-A, KA, FA, KD, SLF, FG, GG, EH, SK, IM, FM, LY, and RB-P declare that they have no conflict of interest.
